• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

CVS Is a Good Place to Hide in a Volatile Marketplace: What Traders Can Do

The firm certainly seems to have the wind at its sails right now.
By STEPHEN GUILFOYLE
Jan 11, 2022 | 10:00 AM EST
Stocks quotes in this article: CVS

CVS Health (CVS) had something to do on Tuesday morning. The firm is planning to present at the JP Morgan Healthcare Conference this morning. Before doing so, however, CVS Health filed an 8K with the SEC announcing increased full year guidance for 2021.

Shareholders will recall that back on November 3rd, CVS posted adjusted Q3 EPS that beat Wall Street, on revenue that also beat Wall Street, and increased full year adjusted EPS guidance at that time from $7.70-$7.80 to $7.90-$8.00. The stock, which has rallied nicely of late, struggled for almost a month after that release. You see, while CVS had raised guidance for adjusted full year EPS, the firm had reduced guidance for full year GAAP EPS due to a rise in the medical benefit ratio (which is benefit costs as a percentage of premium revenues) to roughly 85.8% from about 84% for the comparable year prior period.

Two weeks after that, CVS unveiled their new retail strategy. Two weeks after that, the firm increased the dividend, and increased full year earnings and revenue guidance, while laying out guidance for 2022. A week after that, Bank of America selected CVS as its one stock in the healthcare sector with upside that had largely been largely neglected by active funds but could benefit from inflation.

This Morning

From the 8-K that was filed on Tuesday morning, CVS Health has increased full year 2021 adjusted EPS guidance to $8.33-$8.38 from $8.00+, and increased guidance for full year 2021 EPS guidance to $5.87-$5.92 from $5.50-$5.61. Wall Street had been looking for $8.03 for the adjusted number. The firm simultaneously reaffirmed guidance for FY 2022 GAAP EPS to $7.04-$7.24 and guidance for adjusted 2021 EPS of $8.10-$8.30. Wall Street is at $8.27 on this metric.

CVS will report early in February. For the fourth quarter, a consensus of 23 sell-side analysts covering the name is for adjusted EPS of $1.61 on revenue generation of about $75B. These numbers, if precise (they won't be), would be good for earnings growth of 23.8% on revenue growth of almost 8%.

Focus will be on the Health Care Benefits segment where revenue grew 9.5% for the third quarter to $20.479B, but this is where the higher medical benefits ratio was felt. Pharmacy services remains the firm's largest business. That unit experienced sales growth of 9.3% to $39.046B for the third quarter. Eyes will also be on the Retail Segment, which is currently undergoing an overhaul. This unit posted Q3 sales of $24.992B, which was good for growth of an even 10%.

Fundies

Balance sheet? Not wonderful. If the current ratio, which as of the end of the third quarter, stood below "one" is your only metric. Current assets are outweighed by current liabilities despite a growing cash balance and a boost to receivables. Total assets still easily outweighs total liabilities less equity as the firm has worked toward reducing long-term debt while moving some of that debt into the current column. Free cash flow (levered or not) is still healthy. Still, tangible book value starts with a minus sign. We never love that.

My Thoughts

The shares seem cheap at 13 times forward looking earnings. They are cheap because the fundies could be better. That said, the firm certainly seems to have the wind at its sails right now, and I am long the name. Yes, I took profits a ways back, and missed some of the gravy. That said, with a beta of 0.57, CVS is a good place to hide in a volatile marketplace. In addition, the firm pays shareholders 2.1% or $2.20 per year just to hang around.

The Chart

By every indicator I follow regularly, CVS was coming out of a technically overbought condition on Monday, ahead of raising guidance. Readers will see that from May through early November, CVS built a saucer (because it's' too shallow to be a cup), and then tacked on a handle. The shares are currently working on a breakout provided by a $97 pivot. So if not in the name, you did miss some. I currently have a $116 target price, so it's not time to sell the name (assuming I am right).

A trader with the name could sell February 11th CVS $116 calls against the position for an implied value of about $0.51. A trader interested in getting long the shares without putting up the cash necessary for an equity purchase could sell $101 February 11th puts for about $1.55. The 21 day EMA currently stands at $101, and if the trader were to be tagged with the shares at expiration, that trader's net basis would be $99.45.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long CVS equity.

TAGS: Earnings | Investing | Stocks | Technical Analysis | Trading | Consumer Services | Pharmaceuticals | Retail

More from Investing

Why Would You Want to Own an Apple That's Going Bad?

Bruce Kamich
Sep 26, 2023 2:45 PM EDT

Here's why I wouldn't follow the advice of hold-but-don't trade AAPL.

Williams-Sonoma Stock Jumps After Private Equity Investment

Bruce Kamich
Sep 26, 2023 1:34 PM EDT

Let's see what the charts are telling us now.

Kohl's May Look Like a Bargain, but Buyer Beware

Bruce Kamich
Sep 26, 2023 11:33 AM EDT

Here's my take on the retailer's potential for a short-term bounce, based on the charts.

An Update on My Top Small-Cap Pick and What It Means for the Overall Market

James "Rev Shark" DePorre
Sep 26, 2023 11:30 AM EDT

The good news is that the corrective action is advancing and opportunities are developing.

Target Is Taking Aim at Lower Share Prices in the Weeks Ahead

Bruce Kamich
Sep 26, 2023 11:01 AM EDT

Here's what investors and traders need to know.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:20 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading in Multiple Time Frames
  • 10:24 AM EDT BRUCE KAMICH

    This Could Get Messy

    A number of key stocks are getting close to import...
  • 01:41 PM EDT CHRIS VERSACE

    Latest AAP Podcast With Helene Meisler!

    Listen in as the Action Alerts PLUS podcast talks ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login